TOI 8-K: SEC filing
Starling Oncology, Inc.
Filed with the SEC on · accession 0001079973-26-001469
TOI filed a 8-K (current report) with the SEC on Nov 12, 2026. Starling Oncology, Inc. filed an amendment to its Form 8-K to furnish an updated investor presentation, which replaces and supersedes the presentation filed earlier the same day.
Summary of the filing
Starling Oncology, Inc. filed an amendment to its Form 8-K to furnish an updated investor presentation, which replaces and supersedes the presentation filed earlier the same day. The filing is a routine Regulation FD disclosure with no new material corporate events.
Key details
✦ Ask GOAX AI about this filing — what it means for TOI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TOI?
Click hereFrequently asked questions
What did TOI file with the SEC on Nov 12, 2026?
TOI filed a 8-K (SEC filing). Starling Oncology, Inc. filed an amendment to its Form 8-K to furnish an updated investor presentation, which replaces and supersedes the presentation filed earlier the same day. The filing is a routine Regulation FD disclosure with no new material corporate events.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other TOI SEC filings
Get alerts when TOI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days